Inhibition of Aurora-A improves insulin resistance by ameliorating islet inflammation and controlling interleukin-6 in a diabetic mouse model

References

• Blonde L. Epidemiology, costs, consequences, and pathophysiology of type 2 diabetes: an american epidemic. Ochsner J. 2001;3(3):126–131.
   PubMedGoogle Scholar
• Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes. 2017;9(4):320–344.
   PubMed Web of Science ®Google Scholar
• Ndisang JF, Vannacci A, Rastogi S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res. 2017;2017:p. 1478294.
   PubMed Web of Science ®Google Scholar
• Pedersen BK. IL-6 signalling in exercise and disease. Biochem Soc Trans. 2007;35(5):p. 1295–1297.
   PubMedGoogle Scholar
• Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008;32(6):638–644.
   PubMed Web of Science ®Google Scholar
• Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23(3):133–141.
   PubMed Web of Science ®Google Scholar
• Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer. 2005;5(1):42–50.
   PubMed Web of Science ®Google Scholar
• Tang A, Gao K, Chu L, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937–23954.
   PubMedGoogle Scholar
• Wang J, Nikhil K, Viccaro K, et al. Phosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancer. BMC Biol. 2017;15(1):10.
   PubMedGoogle Scholar
• Hobson A, Draney C, Stratford A, et al. Aurora Kinase A is critical for the Nkx6.1 mediated beta-cell proliferation pathway. Islets. 2015;7(1):e1027854.
   PubMed Web of Science ®Google Scholar
• Yao JE, Yan M, Guan Z, et al. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer. 2009;8(1):95.
   PubMedGoogle Scholar
• Cho MK, An JM, Kim CH, et al. Elevated aurora kinase a protein expression in diabetic skin tissue. Arch Plast Surg. 2014;41(1):35–39.
   PubMedGoogle Scholar
• Deng X, Sun L, Lai X, et al. Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-κB signaling pathway in type 2 diabetes mice. J Agric Food Chem. 2018;66(45):11957–11967.
   PubMed Web of Science ®Google Scholar
• Zhu L, Almaça J, Dadi PK, et al. beta-arrestin-2 is an essential regulator of pancreatic beta-cell function under physiological and pathophysiological conditions. Nat Commun. 2017;8(1):14295.
   PubMedGoogle Scholar
• Zhang B, Gu X, Han X, et al. Crosstalk between DNA methylation and histone acetylation triggers GDNF high transcription in glioblastoma cells. Clin Epigenetics. 2020;12(1):47.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang H, Zhang R, et al. Effects of photoperiod on acetaminophen-induced hepatotoxicity in mice. Dig Dis Sci. 2020;65(1):383 178–188.
   Web of Science ®Google Scholar
• Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2009;87(5):2084–2089.
   Google Scholar
• Tonks KT, Ng Y, Miller S, et al. Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia. 2013;56(4):875–885.
   PubMed Web of Science ®Google Scholar
• Brady MJ, Saltiel AR. Closing in on the cause of insulin resistance and type 2 diabetes. J Clin Invest. 1999;104(6):675–676.
   PubMed Web of Science ®Google Scholar
• Sandler S, Bendtzen K, Eizirik DL, et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology. 1990;126(2):1288–1294.
   PubMed Web of Science ®Google Scholar
• Kanemaki T, Kitade H, Kaibori M, et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology. 1998;27(5):1296–1303.
   PubMed Web of Science ®Google Scholar
• Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 1997;82(12):4167–4170.
   PubMed Web of Science ®Google Scholar
• Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation. 2000;102(1):42–47.
   PubMed Web of Science ®Google Scholar
• Schuett H, Oestreich R, Waetzig GH, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(2):281–290.
   PubMed Web of Science ®Google Scholar
• Ying W, Fu W, Lee YS, et al. The role of macrophages in obesity-associated islet inflammation and beta-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81–90.
   PubMed Web of Science ®Google Scholar
• Lisa SM, Wickbom M, Wang F, et al. Early impairment of insulin secretion in rats after surgical trauma. Eur J Endocrinol. 2002;147(6):825–833.
   PubMed Web of Science ®Google Scholar
• Larsonmeyer DE, Newcomer BR, Ravussin E, et al. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia. 2011;54(4):869–875.
   PubMed Web of Science ®Google Scholar
• Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–520.
   PubMed Web of Science ®Google Scholar
• Noakes TD. So what comes first: the obesity or the insulin resistance? And which is more important? Clin Chem. 2018;64(1):7–9.
   PubMed Web of Science ®Google Scholar
• Altaf QA, Barnett AH, Tahrani AA. Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes Obes Metab. 2015;17(4):319–334.
   PubMed Web of Science ®Google Scholar
• Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):425 363–374.
   Web of Science ®Google Scholar
• Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2):428 191–198.
   Web of Science ®Google Scholar
• Erbağci AB, Tarakçioğlu M, Coşkun Y, et al. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem. 2001;34(8):645–650.
   PubMed Web of Science ®Google Scholar
• Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016;12(1):15–28.
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46):45777–45784.
   PubMed Web of Science ®Google Scholar
• Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45(6):805–812.
   PubMed Web of Science ®Google Scholar
• Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia. 2004;47(7):1135–1142.
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–1292.
   PubMed Web of Science ®Google Scholar